New drug combination for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether combining three treatments—NALIRIFOX (chemotherapy), Adebrelimab (an immune-boosting antibody), and PULSAR (radiation)—can help people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if this combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Pancreatic cancer (ductal adenocarcinoma type) confirmed by biopsy, never treated before, and too advanced to remove surgically or has spread to other organs
- Good overall health and able to care for yourself with minimal help (ECOG score 0–1)
- Expected to live at least 3 months
- Healthy blood counts, liver, and kidney function (based on recent blood work)
- Able to receive radiation therapy without major concerns
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a combination of chemotherapy with two newer drugs (SHR-1701 and apatinib) as the first treatment for advanced pancreatic cancer. The goal is to see if this combination is safe and effective in slowing cancer growth.
This trial tests a new drug (HRS-4642) given with chemotherapy, with or without immunotherapy, before surgery for pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial combines focused radiation with a chemotherapy drug combo to help shrink or control locally advanced pancreatic cancer. If it works, this treatment might make the tumor smaller and improve quality of life.
This trial tests a new combination of drugs (including an investigational immunotherapy and a targeted pill, plus standard chemotherapy) as the first treatment for pancreatic cancer that cannot be removed with surgery. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.